Which claim belongs to which study?
LinkedIn caption
🔎 For incretin drugs and aging, the study design belongs beside the result.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Its exploratory methylation-clock analysis discussed at ARDD 2026 is hypothesis-generating; a clock shift does not establish human rejuvenation.
Keeping those evidence layers separate helps the conversation progress. Established treatment effects, exploratory biological signals and a future healthspan claim ask different questions. The interesting next step is a study designed to test the broader claim, with appropriate controls and outcomes.
#ARDD2026 #GLP1 #Geroscience #ClinicalTrials
X caption
🔎 GLP-1-related research is opening new questions about aging biology. Exploratory tirzepatide clock findings discussed at ARDD offer hypotheses to test; they do not establish human rejuvenation. #ARDD2026 #GLP1 #Geroscience
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
